Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • XRX-225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Annual & Special Meeting of Shareholders
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Analyst Coverage
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Annual & Special Meeting of Shareholders
  • Email Alerts
Nov 03, 2022 5:00pm EDT

XORTX Presents New Proof of Concept Data at American Society of Nephrology

Nov 03, 2022 10:15am EDT

XORTX Announces Participation at Upcoming Investor Conferences

Oct 26, 2022 7:00am EDT

XORTX Receives Further No Objection Letter from Health Canada

Oct 25, 2022 7:00am EDT

XORTX Sponsored American Society of Nephrology Study Abstract Available Online

Oct 07, 2022 6:02pm EDT

XORTX Announces Closing of US$5 Million Public Offering

Oct 04, 2022 8:30am EDT

XORTX Announces US$5 Million Public Offering

Sep 19, 2022 7:00am EDT

XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

Sep 01, 2022 7:00am EDT

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2022

Aug 22, 2022 7:00am EDT

XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

Aug 04, 2022 7:00am EDT

XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …12
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap